Literature DB >> 2056279

Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.

J H Falkenburg1, H M Goselink, D van der Harst, S A van Luxemburg-Heijs, Y M Kooy-Winkelaar, L M Faber, J de Kroon, A Brand, W E Fibbe, R Willemze.   

Abstract

Minor histocompatibility (mH) antigens appear to play a major role in bone marrow transplantation (BMT) using HLA-identical donors. Previously, we reported the isolation of major histocompatibility complex (MHC)-restricted mH antigen-specific cytotoxic T lymphocytes (CTL) from patients with graft-vs.-host disease or rejection after HLA-identical BMT. We have demonstrated that mH antigens can be recognized on hematopoietic progenitor cells, and residual recipient CTL specific for mH antigens expressed on donor hematopoietic progenitor cells may be responsible for graft rejection in spite of intensive conditioning regimens in HLA-identical BMT. Here, we investigated whether mH antigen-specific CTL directed against the mH antigens HA-1 to HA-5 and the male-specific antigen H-Y were capable of antigen-specific inhibition of in vitro growth of clonogenic leukemic precursor cells. We demonstrate that mH antigen-specific CTL against all mH antigens tested can lyse freshly obtained myeloid leukemic cells, that these mH antigen-specific CTL can inhibit their clonogenic leukemic growth in vitro, and that this recognition is MHC restricted. We illustrate that leukemic (precursor) cells can escape elimination by mH antigen-specific CTL by impaired expression of the relevant MHC restriction molecule. We suggest that mH antigen-specific MHC-restricted CTL may be involved in vivo in the graft-vs.-leukemia reactivity after BMT.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2056279      PMCID: PMC2118892          DOI: 10.1084/jem.174.1.27

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  Y-antigen killing by T cells of women is restricted by HLA.

Authors:  E Goulmy; A Termijtelen; B A Bradley; J J van Rood
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

2.  Human erythroid progenitor cells express Rhesus antigens.

Authors:  J H Falkenburg; W E Fibbe; N van der Vaart-Duinkerken; M E Nichols; P Rubinstein; J Jansen
Journal:  Blood       Date:  1985-09       Impact factor: 22.113

3.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.

Authors:  P L Weiden; K M Sullivan; N Flournoy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-06-18       Impact factor: 91.245

4.  Minor histocompatibility antigen H-Y is expressed on human hematopoietic progenitor cells.

Authors:  P J Voogt; E Goulmy; W E Fibbe; W F Veenhof; A Brand; J H Falkenburg
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

5.  How does bone-marrow transplantation cure leukaemia?

Authors:  R P Gale; R E Champlin
Journal:  Lancet       Date:  1984-07-07       Impact factor: 79.321

6.  A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease.

Authors:  E Goulmy; J W Gratama; E Blokland; F E Zwaan; J J van Rood
Journal:  Nature       Date:  1983-03-10       Impact factor: 49.962

7.  Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens.

Authors:  P J Voogt; W E Fibbe; W A Marijt; E Goulmy; W F Veenhof; M Hamilton; A Brand; F E Zwann; R Willemze; J J van Rood
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

8.  Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells.

Authors:  P J Voogt; E Goulmy; W F Veenhof; M Hamilton; W E Fibbe; J J Van Rood; J H Falkenburg
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

9.  Susceptibility of human male keratinocytes to MHC-restricted H-Y-specific lysis.

Authors:  C A van Els; M M de Bueger; J Kempenaar; M Ponec; E Goulmy
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

10.  Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells.

Authors:  W A Marijt; W F Veenhof; A Brand; E Goulmy; W E Fibbe; R Willemze; J J van Rood; J H Falkenburg
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more
  20 in total

Review 1.  Autologous and allogeneic high-dose therapy for melanoma.

Authors:  K A Margolin
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 2.  T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.

Authors:  C Russell Cruz; Catherine M Bollard
Journal:  Haematologica       Date:  2015-06       Impact factor: 9.941

Review 3.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

4.  NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.

Authors:  Jeffrey S Miller; Edus H Warren; Marcel R M van den Brink; Jerome Ritz; Warren D Shlomchik; William J Murphy; A John Barrett; Hans Jochem Kolb; Sergio Giralt; Michael R Bishop; Bruce R Blazar; J H Frederik Falkenburg
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-10       Impact factor: 5.742

5.  CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells.

Authors:  D Bonnet; E H Warren; P D Greenberg; J E Dick; S R Riddell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 6.  Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens.

Authors:  R Champlin; S Giralt; I Khouri
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.075

7.  Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.

Authors:  S Pion; P Fontaine; C Baron; M Gyger; C Perreault
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 8.  Immunotherapy in acute leukemia.

Authors:  Wing Leung
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 9.  Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Tuna Mutis
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

Review 10.  Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.

Authors:  Conrad R Y Cruz; Catherine M Bollard
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.